CellVec

What CellVec does

CellVec is a Singapore-based, privately held biotechnology company founded in 2018 that develops GMP (Good Manufacturing Practice) gene therapy products and custom viral vectors for pre-clinical and clinical applications. The company's stated focus is on serving researchers and biopharma developers who require manufacturing-grade viral vectors and gene therapy constructs across the pre-clinical to clinical development continuum, positioning it as a contract development and manufacturing-style player in the cell and gene therapy supply chain.

Operationally, CellVec employs between 11 and 50 staff and operates from Singapore, a regional hub for Asia-Pacific biotech manufacturing. The company is led by scientific founder Lucas Chan (CSO), suggesting deep technical leadership in viral vector engineering, and has added Gayatri Sharma as Chief Commercial Officer, indicating an intent to commercialize and scale customer-facing operations. The underlying technology platform centers on GMP-compliant viral vector production and gene therapy development — capabilities that require validated cleanroom infrastructure, regulatory-grade quality systems, and process know-how that constitute significant barriers to entry.

The company's business model is implied rather than explicitly documented: as a GMP gene therapy / viral vector supplier serving pre-clinical and clinical customers, revenue most likely derives from project-based or contract manufacturing agreements, milestone-based service fees, and potentially grant or research funding. Notably, the input data provides no disclosed revenue, no funding history, no customer logos, and no pricing details — and the company's website returned only a loading page, indicating limited public commercial transparency at the time of data collection. This evidence thinness constrains a confident assessment of commercial traction and warrants caution in downstream valuation or pipeline analysis.

Name

CellVec

Website

https://cellvec.com

Company type

Private

Founded year

2018

Headcount range

11–50 employees

Short description

CellVec is a Singapore-based private biotech founded in 2018 that develops GMP-grade gene therapy products and custom viral vectors for pre-clinical and clinical-stage biopharma and research customers across the cell and gene therapy development pipeline.

Ownership category

akta.pro rank

Product category

Viral Vector Manufacturing & Gene Therapy Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

akta.pro secondary industries

Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM)

Keywords

• Viral vector manufacturing
• Gene therapy development
• GMP cell therapy
• Custom viral vectors
• Biotechnology CDMO services

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Core offering

CellVec develops GMP gene therapy products and manufactures custom viral vectors for pre-clinical and clinical applications. The company provides contract development and manufacturing services that support biotech and pharmaceutical clients in advancing gene therapy programs from research stages through clinical use.

Differentiator

Problem solved

Functional benefit

Products and services

• GMP Gene Therapy Development Development of GMP-grade gene therapy products intended for pre-clinical and clinical applications, delivered to biotech, pharma, and research clients.
• Custom Viral Vectors Custom-designed viral vector manufacturing services based on biotechnology research, supplied to support pre-clinical and clinical-stage gene and cell therapy programs.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• Lonza Group: Global CDMO leader with substantial viral vector and cell therapy manufacturing capacity. Comparable as a viral vector CDMO serving gene therapy developers, though at much greater scale and breadth than CellVec.
• Catalent (Thermo Fisher Scientific): Major gene therapy CDMO offering AAV and lentiviral vector manufacturing services to clinical and commercial-stage developers. Overlaps directly with CellVec's core offering but at a much larger global scale.
• Charles River Laboratories (Cobra Biologics): Provides viral vector and plasmid DNA manufacturing services through its Cobra Biologics division, serving gene therapy and cell therapy developers. Directly comparable to CellVec in offering custom viral vectors for clinical applications.
• WuXi Advanced Therapies Unit (WuXi AppTec / WuXi Biologics): Asia-based CDMO offering plasmid, viral vector, and cell therapy manufacturing services. Comparable in service offering and a relevant regional competitor given CellVec's Singapore base.
• Thermo Fisher Scientific — Viral Vector Services: Through its Brammer Bio business, Thermo Fisher offers GMP viral vector manufacturing for gene therapy developers. Direct functional competitor and broader life sciences incumbent with global capacity.

Direct peers

• Aldevron: Specialized CDMO producing plasmid DNA, mRNA, and viral vectors for gene therapy and vaccine developers. Direct peer in custom viral vector manufacturing for clinical applications, though larger and US-headquartered.
• Yposkesi: France-based viral vector CDMO focused on AAV and lentiviral manufacturing for gene therapy developers. Closely comparable in scale, specialization, and clinical-stage focus.
• VIVEbiotech: Spain-based CDMO specializing in lentiviral vector production for gene and cell therapy developers. Comparable as a specialized, mid-size viral vector manufacturer serving clinical-stage customers.

Emerging players

• Genezen: US-based viral vector and gene therapy CDMO offering AAV and lentiviral manufacturing services. Comparable emerging player in the same niche CDMO space with a similar growth-stage profile.

Others

• Polyplus (Sartorius) — transfection reagent supplier: Supplies transfection reagents and plasmid DNA used in viral vector manufacturing workflows. Adjacent ecosystem participant whose customers overlap with CellVec's customer base.

Market position

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/cellvechq

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellVec